Cresco Labs, Inc.

As of June 30, 2026, Cresco Labs, Inc. carries a market capitalization of 263.27M, placing it among publicly traded companies globally. Its enterprise value stands at 669.23M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cresco Labs, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Cresco Labs, Inc. has 371.85M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.45, and the price-to-book ratio stands at 0.84.

As of June 30, 2026, Cresco Labs, Inc. trades at an EV/EBITDA multiple of 33.92 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 669.23M versus a market cap of 263.27M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cresco Labs, Inc. maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 224.80, indicating elevated leverage, while an interest coverage ratio of 0.37 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cresco Labs, Inc. posted a negative return on equity (ROE) of -25.13, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.73, reflecting losses generated across the asset base. The company generates approximately 196,529.60 in revenue per employee across its workforce of 2,900.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.25 indicates how many times Cresco Labs, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cresco Labs, Inc. recorded 7.81M in income tax expense. The company reported a pretax loss of -90.71M and -88.33M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Cresco Labs, Inc.'s stock has declined approximately 40.45% over the past 52 weeks. The 50-day moving average sits at 0.62, while the 200-day moving average is 0.75.

Over the twelve months ended June 30, 2026, Cresco Labs, Inc. generated 569.94M in revenue and converted that into -88.33M in net income, yielding earnings per share of -0.25. EBITDA reached 19.73M, while operating income came in at 54.69M.

As of June 30, 2026, Cresco Labs, Inc. holds 28.77M in cash and equivalents against 518.19M in total debt, resulting in a net debt position of 345.15M. Total book value stands at 313.96M, with working capital of 94.49M providing operational flexibility.

Cresco Labs, Inc. produced 37.98M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -33.92M in capital expenditures, free cash flow totaled 4.06M - equivalent to 0.01 per share.

Over the twelve months ended June 30, 2026, Cresco Labs, Inc. posted a gross margin of 49.92, reflecting its pricing power and cost economics. The operating margin of 9.60 and net profit margin of -15.50 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.48, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 28.58, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cresco Labs, Inc. shareholders.

Cresco Labs, Inc.'s most recent stock split took place on November 30, 2018.

As of June 30, 2026, Cresco Labs, Inc. has an Altman Z-Score of -1.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.